Sofpironium

Summary

Sofpironium (CHEMBL3707224) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 390.5 Da · C22H32NO5+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3707224
Name	Sofpironium
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	86301317
Molecular formula	C22H32NO5+
Molecular weight	390.5
InChIKey	SEVCTUCCZYBJER-BSJAROSPSA-N

SMILES: CCOC(=O)C[N+]1(CC[C@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C

IUPAC name: [(3R)-1-(2-ethoxy-2-oxoethyl)-1-methylpyrrolidin-1-ium-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate

Also known as: Bbi-4000 ion, Sofpironium cation

Parent form; salt/anhydrous children: CHEMBL3707223

Patent coverage: 8 distinct patent families (18 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).